Zalea Pitch Concepts
The Brief
Patients with PIDD have weakened immune systems and are often dealing with additional comorbidities. As a result, patients (and caregivers) are limited in their daily activities and require a treatment that is well tolerated.
Through GALISTA 20% SCIG, patients gain their freedom from PIDD. Because it is administrated subcutaneously, patients can receive therapy at their convenience, on their schedule.
The Assignment
Establish GALISTA as the 20% SCIG brand with the ideal Ig formulation, and as the well-tolerated product for even the most sensitive immunodeficient/Primary Immune Deficiency(PIDD) patient types
CONCEPT 1
Refined Performance
Inspirational Mood Board – Accentuate the purity of the new formulation along with the added freedom for patients
Sketch Concept
CONCEPT 2
Empowerment you can see
Inspirational Mood Board – The new 20% SCIG gives patients greater protection to allow them more freedom. Visually depict a protective aura around them that also shapes like the "Y" anti-bodies.
Sketch Concept
